Immunological considerations for COVID-19 vaccine strategies (original) (raw)

• World Health Organization. WHO coronavirus disease (COVID-19) dashboard. WHO https://covid19.who.int/ (2020).
• Chou, R. et al. Epidemiology of and risk factors for coronavirus infection in health care workers. Ann. Intern. Med. https://doi.org/10.7326/M20-1632 (2020).
  Article PubMed PubMed Central Google Scholar
• Flaxman, S. et al. Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe. Nature 584, 257–261 (2020).
  Article CAS PubMed Google Scholar
• Sanche, S. et al. High contagiousness and rapid spread of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 26, 1470–1477 (2020).
  Article PubMed PubMed Central Google Scholar
• World Health Organization. Draft landscape of COVID-19 candidate vaccines. WHO https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines (2020).
• Lurie, N., Saville, M., Hatchett, R. & Halton, J. Developing Covid-19 vaccines at pandemic speed. N. Engl. J. Med. 382, 1969–1973 (2020). This article describes the differences between the pandemic vaccine development and the conventional rationalized vaccine development paradigms and timelines.
  Article CAS PubMed Google Scholar
• Chau, N. V. V. et al. The natural history and transmission potential of asymptomatic SARS-CoV-2 infection. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa711 (2020).
• Poletti, P. et al. Probability of symptoms and critical disease after SARS-CoV-2 infection. Preprint at arXiv https://arxiv.org/abs/2006.08471 (2020). Chau et al. (2020) and Poletti et al. indicate high rates of asymptomatic individuals following SARS-CoV-2 exposure.
• Long, Q.-X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020). This study provides evidence that asymptomatic individuals infected with SARS-CoV-2 can shed the virus for a significantly longer time than their symptomatic counterparts and that immune responses, including antibody responses, in asymptomatic individuals are not only lower but also decrease faster during the convalescent phase.
  Article CAS PubMed Google Scholar
• Sungnak, W. et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 26, 681–687 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Zou, X. et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front. Med. 14, 185–192 (2020).
  Article PubMed Google Scholar
• Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8 (2020). This is one of the first studies to identify ACE2 and TMPRSS2 as the cell surface receptor molecules used by SARS-CoV-2 for infection.
  Article CAS PubMed PubMed Central Google Scholar
• Sallenave, J.-M. & Guillot, L. Innate immune signaling and proteolytic pathways in the resolution or exacerbation of SARS-CoV-2 in Covid-19: key therapeutic targets? Front. Immunol. 11, 1229 (2020).
  Article PubMed PubMed Central Google Scholar
• Puelles, V. G. et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 383, 590–592 (2020).
  Article PubMed Google Scholar
• de Wit, E., van Doremalen, N., Falzarano, D. & Munster, V. J. SARS and MERS: recent insights into emerging coronaviruses. Nat. Rev. Microbiol. 14, 523–534 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Prompetchara, E., Ketloy, C. & Palaga, T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac. J. Allergy Immunol. 38, 1–9 (2020).
  PubMed Google Scholar
• Sariol, A. & Perlman, S. Lessons for COVID-19 immunity from other coronavirus infections. Immunity https://doi.org/10.1016/j.immuni.2020.07.005 (2020).
• Zhou, R. et al. Acute SARS-CoV-2 infection impairs dendritic cell and T cell responses. Immunity 53, 1–14 (2020). This study documents SARS-CoV-2-mediated innate immune suppression associated with impaired dendritic cell responses and, subsequently, delayed T cell activation in infected individuals.
  Article CAS Google Scholar
• Remy, K. E. et al. Severe immunosuppression and not a cytokine storm characterize COVID-19 infections. JCI Insight https://doi.org/10.1172/jci.insight.140329 (2020).
  Article PubMed PubMed Central Google Scholar
• Blanco-Melo, D. et al. Imbalanced host response to SARS-CoV-2 drives development of COVID-19. Cell 181, 1036–1045.e9 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Merad, M. & Martin, J. C. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 20, 355–362 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, Y. et al. Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci. Rev. 7, 998–1002 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 26, 842–844 (2020).
  Article CAS PubMed Google Scholar
• Fulop, T. et al. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes? Front. Immunol. 8, 1960 (2017).
  Article PubMed CAS Google Scholar
• Haq, K. & McElhaney, J. E. Immunosenescence: influenza vaccination and the elderly. Curr. Opin. Immunol. 29, 38–42 (2014). Fulop et al. (2017) and Haq and McElhaney discuss a unique challenge for developing effective and safe vaccine strategies for seniors, who are among those most in need of vaccine-mediate immune protection from COVID-19, and suggest that vaccine-induced T cell immunity is more important than antibody responses in seniors.
  Article CAS PubMed Google Scholar
• Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A. & Ng, L. F. P. The trinity of COVID-19: immunity, inflammation and intervention. Nat. Rev. Immunol. 20, 363–374 (2020).
  Article CAS PubMed Google Scholar
• Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa344 (2020).
  Article PubMed PubMed Central Google Scholar
• Ni, L. et al. Detection of SARS-CoV-2-specific humoral and cellular immunity in COVID-19 convalescent individuals. Immunity 52, 971–977.e3 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Grifoni, A. et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell 181, 1489–1501.e15 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Shen, C. et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA 323, 1582 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Seow, J. et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection. Preprint at medRxiv https://doi.org/10.1101/2020.07.09.20148429 (2020). This study follows the kinetic changes in neutralizing antibody levels up to 94 days after the onset of COVID-19 symptoms; it finds that antibody levels are positively correlated with the severity of disease and decline rapidly, bringing into question the value of serological assessment and the role of such neutralizing antibodies in herd immunity.
  Article Google Scholar
• Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181, 281–292.e6 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290–295 (2020).
  Article CAS PubMed Google Scholar
• Jiang, S., Hillyer, C. & Du, L. Neutralizing antibodies against SARS-CoV-2 and other human coronaviruses. Trends Immunol. 41, 355–359 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Duan, J. et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem. Biophys. Res. Commun. 333, 186–193 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Coughlin, M. et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse®. Virology 361, 93–102 (2007).
  Article CAS PubMed Google Scholar
• To, K. K. W. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study. Lancet Infect. Dis. 20, 565–574 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Liu, W. et al. Evaluation of nucleocapsid and spike protein-based enzyme-linked immunosorbent assays for detecting antibodies against SARS-CoV-2. J. Clin. Microbiol. 58, e00461-20 (2020).
  Article PubMed PubMed Central Google Scholar
• Long, Q. X. et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. Nat. Med. 26, 845–848 (2020).
  Article CAS PubMed Google Scholar
• Nakanaga, K., Yamanouchi, K. & Fujiwara, K. Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice. J. Virol. 59, 168–171 (1986).
  Article CAS PubMed PubMed Central Google Scholar
• Lecomte, J. et al. Protection from mouse hepatitis virus type 3-induced acute disease by an anti-nucleoprotein monoclonal antibody. Arch. Virol. 97, 123–130 (1987).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, H. et al. Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients. Eur. Respir. J. https://doi.org/10.1183/13993003.01526-2020 (2020).
  Article PubMed PubMed Central Google Scholar
• Padoan, A. et al. IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: a longitudinal study. Clin. Chim. Acta 507, 164–166 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F. & Richardus, J. H. Disappearance of antibodies to SARS-associated coronavirus after recovery. N. Engl. J. Med. 357, 1162–1163 (2007).
  Article CAS PubMed Google Scholar
• Wu, L. P. et al. Duration of antibody responses after severe acute respiratory syndrome. Emerg. Infect. Dis. 13, 1562–1564 (2007).
  Article PubMed PubMed Central Google Scholar
• Callow, K. A., Parry, H. F., Sergeant, M. & Tyrrell, D. A. J. The time course of the immune response to experimental coronavirus infection of man. Epidemiol. Infect. 105, 435–446 (1990).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, K. & Kolls, J. K. T cell–mediated host immune defenses in the lung. Annu. Rev. Immunol. 31, 605–633 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Arunachalam, P. S. et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat. Med. 26, 932–940 (2020). This non-human primate study compares a vaccine strategy focused on inducing neutralizing antibodies with a vaccine that induces both neutralizing antibodies and T cell-mediated immunity, including vaginal T RM cells, and describes the importance of protective T cells, particularly when neutralizing antibody levels are suboptimal. This study lends further support to including robust T cell responses in the design of COVID-19 vaccine strategies.
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, J., Zhao, J. & Perlman, S. T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J. Virol. 84, 9318–9325 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Turner, D. L. et al. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 7, 501–510 (2014).
  Article CAS PubMed Google Scholar
• Jeyanathan, M., Yao, Y., Afkhami, S., Smaill, F. & Xing, Z. New tuberculosis vaccine strategies: taking aim at un-natural immunity. Trends Immunol. 39, 419–433 (2018). This recent review highlights the major immunological differences and protective outcomes between parenteral and respiratory mucosal routes of vaccination and suggests ways in which to induce holistic mucosal immunity to mucosal pathogens.
  Article CAS PubMed Google Scholar
• Haddadi, S. et al. Mucosal-pull induction of lung-resident memory CD8 T cells in parenteral TB vaccine-primed hosts requires cognate antigens and CD4 T Cells. Front. Immunol. 10, 2075 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, J. et al. Airway memory CD4+ T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 44, 1379–1391 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Janice Oh, H.-L., Ken-En Gan, S., Bertoletti, A. & Tan, Y.-J. Understanding the T cell immune response in SARS coronavirus infection. Emerg. Microbes Infect. 1, 1–6 (2012).
  Article CAS Google Scholar
• Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Tseng, C.-T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Braun, J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature https://doi.org/10.1038/s41586-020-2598-9 (2020).
  Article PubMed PubMed Central Google Scholar
• Ahmed, S. F., Quadeer, A. A. & McKay, M. R. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses 12, 254 (2020).
  Article CAS PubMed Central Google Scholar
• Mateus, J. et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science https://doi.org/10.1126/science.abd3871 (2020).
  Article PubMed PubMed Central Google Scholar
• Le Bert, N. et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature https://doi.org/10.1038/s41586-020-2550-z (2020). Braun et al. (2020), Mateus et al. (2020) and Le Bert et al. consistently find the presence, in a significant proportion of uninfected individuals, of memory CD4 + T cells cross-reactive to SARS-CoV-2, likely resulting from previous exposure to common cold coronaviruses as well as animal coronaviruses. These findings offer a potential mechanism underlying differential susceptibility to SARS-CoV-2 infection and suggest that a COVID-19 vaccine may boost such pre-existing cross-reactive memory T cells in some individuals.
• Screaton, G., Mongkolsapaya, J., Yacoub, S. & Roberts, C. New insights into the immunopathology and control of dengue virus infection. Nat. Rev. Immunol. 15, 745–759 (2015).
  Article CAS PubMed Google Scholar
• Aguiar, J. A. et al. Gene expression and in situ protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. Eur. Respir. J. https://doi.org/10.1183/13993003.01123-2020 (2020).
  Article PubMed PubMed Central Google Scholar
• Mehta, P. et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 395, 1033–1034 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Schulert, G. S. & Grom, A. A. Pathogenesis of macrophage activation syndrome and potential for cytokine-directed therapies. Annu. Rev. Med. 66, 145–159 (2015).
  Article CAS PubMed Google Scholar
• Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Chakraborty, S. et al. Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. Preprint at medRxiv https://doi.org/10.1101/2020.05.15.20103341 (2020).
  Article PubMed PubMed Central Google Scholar
• Lee, N. et al. Anti-SARS-CoV IgG response in relation to disease severity of severe acute respiratory syndrome. J. Clin. Virol. 35, 179–184 (2006).
  Article CAS PubMed Google Scholar
• Liu, L. et al. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection. JCI Insight 4, e123158 (2019).
  Article PubMed Central Google Scholar
• Eroshenko, N. et al. Implications of antibody-dependent enhancement of infection for SARS-CoV-2 countermeasures. Nat. Biotechnol. 38, 789–791 (2020).
  Article CAS PubMed Google Scholar
• Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672–12676 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273–2279 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Kam, Y. W. et al. Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcγRII-dependent entry into B cells in vitro. Vaccine 25, 729–740 (2007).
  Article CAS PubMed Google Scholar
• Diamond, M. S. & Pierson, T. C. The challenges of vaccine development against a new virus during a pandemic. Cell Host Microbe 27, 699–703 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Buchholz, U. J. et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl Acad. Sci. 101, 9804–9809 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Stephensen, C. B., Casebolt, D. B. & Gangopadhyay, N. N. Phylogenetic analysis of a highly conserved region of the polymerase gene from 11 coronaviruses and development of a consensus polymerase chain reaction assay. Virus Res. 60, 181–189 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, Y. et al. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science 368, 779–782 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Rauch, S., Jasny, E., Schmidt, K. E. & Petsch, B. New vaccine technologies to combat outbreak situations. Front. Immunol. 9, 1963 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Afkhami, S., Yao, Y. & Xing, Z. Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens. Mol. Ther. Methods Clin. Dev. 3, 16030 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Moreno-Fierros, L., García-Silva, I. & Rosales-Mendoza, S. Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Expert. Opin. Biol. Ther. 20, 831–836 (2020).
  Article PubMed Google Scholar
• Belyakov, I. M. & Ahlers, J. D. What role does the route of immunization play in the generation of protective immunity against mucosal pathogens? J. Immunol. 183, 6883–6892 (2009).
  Article CAS PubMed Google Scholar
• Szabo, P. A., Miron, M. & Farber, D. L. Location, location, location: tissue resident memory T cells in mice and humans. Sci. Immunol. 4, eaas9673 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Xing, Z. et al. Innate immune memory of tissue-resident macrophages and trained innate immunity: re-vamping vaccine concept and strategies. J. Leukoc. Biol. https://doi.org/10.1002/JLB.4MR0220-446R (2020).
  Article PubMed Google Scholar
• Netea, M. G. et al. Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection. Cell 181, 969–977 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Yao, Y. et al. Induction of autonomous memory alveolar macrophages requires T cell help and is critical to trained immunity. Cell 175, 1634–1650.e17 (2018). Xing et al. (2020), Netea et al. (2020) and Yao et al. describe the emerging concept of trained innate immunity and suggest strategies to harness this concept for developing vaccines against respiratory mucosal pathogens such as SARS-CoV-2.
  Article CAS PubMed Google Scholar
• Plotkin, S. History of vaccination. Proc. Natl Acad. Sci. USA 111, 12283–12287 (2014).
  Article CAS PubMed PubMed Central Google Scholar
• Almazán, F. et al. Engineering a replication-competent, propagation-defective middle east respiratory syndrome coronavirus as a vaccine candidate. MBio 4, e00650-13 (2013).
  Article PubMed PubMed Central CAS Google Scholar
• Netland, J. et al. Immunization with an attenuated severe acute respiratory syndrome coronavirus deleted in E protein protects against lethal respiratory disease. Virology 399, 120–128 (2010).
  Article CAS PubMed Google Scholar
• Hou, Y., Meulia, T., Gao, X., Saif, L. J. & Wang, Q. Deletion of both the tyrosine-based endocytosis signal and the endoplasmic reticulum retrieval signal in the cytoplasmic tail of spike protein attenuates porcine epidemic diarrhea virus in pigs. J. Virol. 93, e01758-18 (2018).
  Article Google Scholar
• Jimenez-Guardeño, J. M. et al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine. PLoS Pathog. 11, e1005215 (2015).
  Article PubMed PubMed Central CAS Google Scholar
• Menachery, V. D. et al. Attenuation and restoration of severe acute respiratory syndrome coronavirus mutant lacking 2’-O-methyltransferase activity. J. Virol. 88, 4251–4264 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Cheng, B. Y. H., Ortiz-Riaño, E., Nogales, A., de la Torre, J. C. & Martínez-Sobrido, L. Development of live-attenuated arenavirus vaccines based on codon deoptimization. J. Virol. 89, 3523–3533 (2015).
  Article CAS PubMed PubMed Central Google Scholar
• Mueller, S. et al. A codon-pair deoptimized live-attenuated vaccine against respiratory syncytial virus is immunogenic and efficacious in non-human primates. Vaccine 38, 2943–2948 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Tao, Y. et al. Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history. J. Virol. 91, e01953-16 (2017).
  Article PubMed PubMed Central Google Scholar
• Humphreys, I. R. & Sebastian, S. Novel viral vectors in infectious diseases. Immunology 153, 1–9 (2018).
  Article CAS PubMed Google Scholar
• Draper, S. J. & Heeney, J. L. Viruses as vaccine vectors for infectious diseases and cancer. Nat. Rev. Microbiol. 8, 62–73 (2010).
  Article CAS PubMed Google Scholar
• Cohen, J. Top U.S. scientists left out of White House selection of COVID-19 vaccine short list. Science https://doi.org/10.1126/science.abd1719 (2020).
  Article PubMed PubMed Central Google Scholar
• Zhu, F.-C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845–1854 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, F.-C. et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet https://doi.org/10.1016/S0140-6736(20)31605-6 (2020). The phase I and phase II human studies by Zhu et al. evaluate an Ad5-vectored COVID-19 vaccine expressing the S protein, representing the first COVID-19 vaccine globally that entered clinical trials and published results. Pre-existing vector immunity occurred in a significant portion of trial participants.
  Article PubMed PubMed Central Google Scholar
• Smaill, F. et al. A human type 5 adenovirus-based tuberculosis vaccine induces robust T cell responses in humans despite preexisting anti-adenovirus immunity. Sci. Transl Med. 5, 205ra134 (2013).
  Article PubMed CAS Google Scholar
• Ledgerwood, J. E. et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine 29, 304–313 (2010).
  Article CAS PubMed Google Scholar
• Gray, G. E. et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study. Lancet. Infect. Dis. 11, 507–515 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Xiang, Z. et al. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg. Infect. Dis. 12, 1596–1599 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Zhu, F.-C. et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 389, 621–628 (2017).
  Article CAS PubMed Google Scholar
• Cross, R. CanSino publishes first COVID-19 vaccine data to muted response. Chemical & Engineering News https://cen.acs.org/pharmaceuticals/vaccines/CanSino-publishes-first-COVID-19/98/i21 (2020).
• Zhang, S. et al. Seroprevalence of neutralizing antibodies to human adenoviruses type-5 and type-26 and chimpanzee adenovirus type-68 in healthy Chinese adults. J. Med. Virol. 85, 1077–1084 (2013). Xiang et al. (2006) and Zhang et al. compare the prevalence of pre-existing circulating neutralizing antibodies (antivector immunity) to Ad5, Ad26 and ChAd platforms in various parts of the world. The relative prevalence of pre-existing antivector immunity is of importance for the choice of viral platforms.
  Article CAS PubMed Google Scholar
• Colloca, S. et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci. Transl Med. 4, 115ra2 (2012).
  Article PubMed PubMed Central CAS Google Scholar
• Baden, L. R. et al. First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001). J. Infect. Dis. 207, 240–247 (2013).
  Article CAS PubMed Google Scholar
• Anywaine, Z. et al. Safety and immunogenicity of a 2-dose heterologous vaccination regimen with Ad26.ZEBOV and MVA-BN-Filo Ebola vaccines: 12-month data from a phase 1 randomized clinical trial in Uganda and Tanzania. J. Infect. Dis. 220, 46–56 (2019).
  Article CAS PubMed PubMed Central Google Scholar
• Mercado, N. B. et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature https://doi.org/10.1038/s41586-020-2607-z (2020).
  Article PubMed PubMed Central Google Scholar
• Ewer, K. et al. Chimpanzee adenoviral vectors as vaccines for outbreak pathogens. Hum. Vaccin. Immunother. 13, 3020–3032 (2017).
  Article PubMed PubMed Central Google Scholar
• Folegatti, P. M. et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet. Infect. Dis. 20, 816–826 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Wilkie, M. et al. A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults. Vaccine 38, 779–789 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• van Doremalen, N. et al. ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature https://doi.org/10.1038/s41586-020-2608-y (2020).
  Article PubMed PubMed Central Google Scholar
• Folegatti, P. M. et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet https://doi.org/10.1016/S0140-6736(20)31604-4 (2020). This clinical phase I/II study evaluates a ChAd-vectored COVID-19 vaccine expressing the S protein, showing induction of strong neutralizing antibody and overall T cell responses and representing the third published human COVID-19 vaccine trial in the world. This vaccine is the most advanced COVID-19 vaccine candidate in terms of clinical development.
  Article PubMed PubMed Central Google Scholar
• Henao-Restrepo, A. M. et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet 386, 857–866 (2015).
  Article CAS PubMed Google Scholar
• Cohen, J. Merck, one of Big Pharma’s biggest players, reveals its COVID-19 vaccine and therapy plans. Science https://doi.org/10.1126/science.abd0121 (2020).
• Case, J. B. et al. Replication-competent vesicular stomatitis virus vaccine vector protects against SARS-CoV-2-mediated pathogenesis in mice. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.07.018 (2020).
  Article PubMed PubMed Central Google Scholar
• Yahalom-Ronen, Y. et al. A single dose of recombinant VSV-ΔG-spike vaccine provides protection against SARS-CoV-2 challenge. Preprint at bioRxiv https://doi.org/10.1101/2020.06.18.160655 (2020).
  Article Google Scholar
• Koch, T. et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect. Dis. 20, 827–838 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Murdin, A. D., Barreto, L. & Plotkin, S. Inactivated poliovirus vaccine: past and present experience. Vaccine 14, 735–746 (1996).
  Article CAS PubMed Google Scholar
• Vellozzi, C. et al. Safety of trivalent inactivated influenza vaccines in adults: background for pandemic influenza vaccine safety monitoring. Vaccine 27, 2114–2120 (2009).
  Article CAS PubMed Google Scholar
• Wood, J. M. & Robertson, J. S. From lethal virus to life-saving vaccine: developing inactivated vaccines for pandemic influenza. Nat. Rev. Microbiol. 2, 842–847 (2004).
  Article CAS PubMed Google Scholar
• Tahir Ul Qamar, M. et al. Epitope-based peptide vaccine design and target site depiction against Middle East respiratory syndrome coronavirus: an immune-informatics study. J. Transl Med. 17, 362 (2019).
  Article PubMed PubMed Central CAS Google Scholar
• Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330–333 (2020).
  CAS PubMed PubMed Central Google Scholar
• Wang, H. et al. Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell 182, 713–721.e9 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Gao, Q. et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 369, 77–81 (2020).
  Article CAS PubMed Google Scholar
• Zeng, L. Mucosal adjuvants: opportunities and challenges. Hum. Vaccin. Immunother. 12, 2456–2458 (2016).
  Article PubMed PubMed Central Google Scholar
• Iwata-Yoshikawa, N. et al. Effects of toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J. Virol. 88, 8597–8614 (2014).
  Article PubMed PubMed Central CAS Google Scholar
• Del Giudice, G., Rappuoli, R. & Didierlaurent, A. M. Correlates of adjuvanticity: a review on adjuvants in licensed vaccines. Semin. Immunol. 39, 14–21 (2018).
  Article PubMed CAS Google Scholar
• HogenEsch, H., O’Hagan, D. T. & Fox, C. B. Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want. NPJ Vaccines 3, 51 (2018).
  Article PubMed PubMed Central Google Scholar
• Mou, H. et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379–9383 (2013).
  Article CAS PubMed PubMed Central Google Scholar
• Guo, Y. et al. Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 24, 510–515 (2005).
  Article CAS PubMed Google Scholar
• Zhou, Y., Jiang, S. & Du, L. Prospects for a MERS-CoV spike vaccine. Expert. Rev. Vaccines 17, 677–686 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Oscherwitz, J. The promise and challenge of epitope-focused vaccines. Hum. Vaccin. Immunother. 12, 2113–2116 (2016).
  Article PubMed PubMed Central Google Scholar
• Du, L. et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393, 144–150 (2009).
  Article CAS PubMed Google Scholar
• Donaldson, B., Lateef, Z., Walker, G. F., Young, S. L. & Ward, V. K. Virus-like particle vaccines: immunology and formulation for clinical translation. Expert. Rev. Vaccines 17, 833–849 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Lu, X. et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology 122, 496–502 (2007).
  Article CAS PubMed PubMed Central Google Scholar
• Lokugamage, K. G. et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine 26, 797–808 (2008).
  Article CAS PubMed Google Scholar
• Naskalska, A. et al. Novel coronavirus-like particles targeting cells lining the respiratory tract. PLoS ONE 13, e0203489 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Business Wire. Medicago announces positive results in animal trials for its vaccine candidate against COVID-19. STT https://www.sttinfo.fi/tiedote/medicago-announces-positive-results-in-animal-trials-for-its-vaccine-candidate-against-covid-19?publisherId=58763726&releaseId=69881188 (2020).
• Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines - a new era in vaccinology. Nat. Rev. Drug. Discov. 17, 261–279 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).
  Article PubMed PubMed Central Google Scholar
• Lutz, J. et al. Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines. NPJ Vaccines 2, 29 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Corbett, K. S. et al. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature https://doi.org/10.1038/s41586-020-2622-0 (2020).
  Article PubMed PubMed Central Google Scholar
• Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2 - preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2022483 (2020). This clinical phase I study evaluates an mRNA-based COVID-19 vaccine expressing the S protein, showing induction of strong neutralizing antibody and CD4 + T cell responses in most participants and representing the second published human COVID-19 vaccine trial in the world.
  Article PubMed PubMed Central Google Scholar
• Mulligan, M. J. et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature https://doi.org/10.1038/s41586-020-2639-4 (2020).
  Article PubMed Google Scholar
• Sahin, U. et al. Concurrent human antibody and TH1 type T-cell responses elicited by a COVID-19 RNA vaccine. Preprint at medRxiv https://doi.org/10.1101/2020.07.17.20140533 (2020).
  Article PubMed PubMed Central Google Scholar
• Petsch, B. et al. Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza A virus infection. Nat. Biotechnol. 30, 1210–1216 (2012).
  Article CAS PubMed Google Scholar
• Chahal, J. S. et al. Dendrimer-RNA nanoparticles generate protective immunity against lethal Ebola, H1N1 influenza, and Toxoplasma gondii challenges with a single dose. Proc. Natl Acad. Sci. USA 113, E4133–E4142 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Schnee, M. et al. An mRNA vaccine encoding rabies virus glycoprotein induces protection against lethal infection in mice and correlates of protection in adult and newborn pigs. PLoS Negl. Trop. Dis. 10, e0004746 (2016).
  Article PubMed PubMed Central CAS Google Scholar
• Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Pardi, N. et al. Zika virus protection by a single low-dose nucleoside-modified mRNA vaccination. Nature 543, 248–251 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Chahal, J. S. et al. An RNA nanoparticle vaccine against Zika virus elicits antibody and CD8 + T cell responses in a mouse model. Sci. Rep. 7, 252 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Alberer, M. et al. Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial. Lancet 390, 1511–1520 (2017).
  Article CAS PubMed Google Scholar
• Hobernik, D. & Bros, M. DNA vaccines—how far from clinical use? Int. J. Mol. Sci. 19, 3605 (2018).
  Article CAS PubMed Central Google Scholar
• Smith, T. R. F. et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat. Commun. 11, 2601 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Yu, J. et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science https://doi.org/10.1126/science.abc6284 (2020).
  Article PubMed PubMed Central Google Scholar
• Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559–567 (2014).
  Article CAS PubMed Google Scholar
• Mohn, K. G.-I., Smith, I., Sjursen, H. & Cox, R. J. Immune responses after live attenuated influenza vaccination. Hum. Vaccin. Immunother. 14, 571–578 (2018).
  Article PubMed PubMed Central Google Scholar
• Low, N. et al. A randomized, controlled trial of an aerosolized vaccine against measles. N. Engl. J. Med. 372, 1519–1529 (2015).
  Article PubMed Google Scholar
• Satti, I. et al. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial. Lancet Infect. Dis. 14, 939–946 (2014). Mohn et al. (2018), Low et al. (2015) and Satti et al. provide three successful examples of implementing respiratory mucosal delivery of virus-based vaccines to humans, each against a different type of respiratory mucosal pathogen.
  Article CAS PubMed PubMed Central Google Scholar
• Burton, D. R. & Walker, L. M. Rational vaccine design in the time of COVID-19. Cell Host Microbe 27, 695–698 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• World Economic Forum. 3 challenges in creating a coronavirus vaccine – and how they are being overcome. World Economic Forum https://www.weforum.org/agenda/2020/05/coronavirus-covid-19-vaccine-industry/ (2020). This commentary identifies the three biggest hurdles to COVID-19 vaccine development and vaccination implementation as developing and selecting the safest and most effective vaccine, acquiring large-scale manufacturing capacities and ensuring transparent and fair vaccine distribution.
• Bollyky, T. J., Gostin, L. O. & Hamburg, M. A. The equitable distribution of COVID-19 therapeutics and vaccines. JAMA 323, 2462 (2020).
  Article CAS PubMed Google Scholar
• Laczkó, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity https://doi.org/10.1016/j.immuni.2020.07.019 (2020).
• McKay, P. F. et al. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice. Nat. Commun. 11, 3523 (2020).
  Article PubMed PubMed Central CAS Google Scholar
• Sánchez-Ramón, S. et al. Trained immunity-based vaccines: a new paradigm for the development of broad-spectrum anti-infectious formulations. Front. Immunol. 9, 2936 (2018).
  Article PubMed PubMed Central CAS Google Scholar
• Netea, M. G. et al. Defining trained immunity and its role in health and disease. Nat. Rev. Immunol. 20, 375–388 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• de Bree, L. C. J. et al. Non-specific effects of vaccines: current evidence and potential implications. Semin. Immunol. 39, 35–43 (2018).
  Article PubMed CAS Google Scholar
• Uthayakumar, D. et al. Non-specific effects of vaccines illustrated through the BCG example: from observations to demonstrations. Front. Immunol. 9, 2869 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Kaufmann, E. et al. BCG educates hematopoietic stem cells to generate protective innate immunity against tuberculosis. Cell 172, 176–190.e19 (2018).
  Article CAS PubMed Google Scholar
• Cirovic, B. et al. BCG vaccination in humans elicits trained immunity via the hematopoietic progenitor compartment. Cell Host Microbe https://doi.org/10.1016/j.chom.2020.05.014 (2020).
  Article PubMed PubMed Central Google Scholar
• Arts, R. J. W. et al. BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity. Cell Host Microbe 23, 89–100.e5 (2018).
  Article CAS PubMed Google Scholar
• Verrall, A. J. et al. Early clearance of mycobacterium tuberculosis is associated with increased innate immune responses. J. Infect. Dis. 221, 1342–1350 (2019).
  Google Scholar
• Moorlag, S. J. C. F. M., Arts, R. J. W., van Crevel, R. & Netea, M. G. Non-specific effects of BCG vaccine on viral infections. Clin. Microbiol. Infect. 25, 1473–1478 (2019).
  Article CAS PubMed Google Scholar
• Covián, C., Retamal-Díaz, A., Bueno, S. M., Kalergis, A. M. & Could, B. C. G. Vaccination induce protective trained immunity for SARS-CoV-2? Front. Immunol. 11, 970 (2020).
  Article PubMed PubMed Central Google Scholar
• O’Neill, L. A. J. & Netea, M. G. BCG-induced trained immunity: can it offer protection against COVID-19? Nat. Rev. Immunol. 20, 335–337 (2020). This is an overview of the current global effort in clinically testing the potential non-specific protective effect of BCG, a human TB vaccine, on controlling COVID-19 infection and severity, based on the concept of trained innate immunity.
  Article PubMed CAS PubMed Central Google Scholar
• Ordovas-Montanes, J., Beyaz, S., Rakoff-Nahoum, S. & Shalek, A. K. Distribution and storage of inflammatory memory in barrier tissues. Nat. Rev. Immunol. 20, 308–320 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Cardani, A., Boulton, A., Kim, T. S. & Braciale, T. J. Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells. PLoS Pathog. 13, e1006140 (2017).
  Article PubMed PubMed Central CAS Google Scholar
• Guillon, A. et al. Pneumonia recovery reprograms the alveolar macrophage pool. JCI Insight 5, e133042 (2020).
  Article PubMed Central Google Scholar
• Lakdawala, S. S. & Menachery, V. D. The search for a COVID-19 animal model. Science 368, 942–943 (2020).
  Article CAS PubMed Google Scholar
• Wan, Y., Shang, J., Graham, R., Baric, R. S. & Li, F. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J. Virol. 94, e00127-20 (2020).
  Article PubMed PubMed Central Google Scholar
• Rockx, B. et al. Comparative pathogenesis of COVID-19, MERS, and SARS in a nonhuman primate model. Science 368, 1012–1015 (2020).
  Article CAS PubMed PubMed Central Google Scholar
• Munster, V. J. et al. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature https://doi.org/10.1038/s41586-020-2324-7 (2020).
  Article PubMed PubMed Central Google Scholar
• Shi, J. et al. Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS–coronavirus 2. Science 368, 1016–1020 (2020). Together with Lakdawala and Menachery (2020), Shi et al. provide information on the pros and cons of various animal models of COVID-19 for pathogenesis, immunity and vaccine studies.
  Article CAS PubMed PubMed Central Google Scholar
• Zhao, X. et al. Broad and differential animal ACE2 receptor usage by SARS-CoV-2. J. Virol. https://doi.org/10.1128/JVI.00940-20 (2020).
  Article PubMed PubMed Central Google Scholar
• Bao, L. et al. The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice. Nature 583, 830–833 (2020).
  Article CAS PubMed Google Scholar